Biodexa enrolls 100th patient in Serenta Phase 3 eRapa trial in familial adenomatous polyposis
Biodexa reached 100 enrolled patients in the Serenta registrational Phase 3 trial of eRapa in familial adenomatous polyposis. No trial results were presented; the next readout is a pre-specified futility analysis expected early next year. Management expects the study’s key interim decision point sooner than planned, ba